Emerald Clinical

Could APAC be the difference between hitting your Oncology development milestones on time... or falling six months behind? In our latest webinar, Luke S. Gill, Head of Oncology, Will Chen, Global Head of Regulatory Affairs, together with Dr. Rokoyo Nochi of EPS, explored how early integration of China and Japan into global Oncology programs can accelerate enrolment, strengthen development strategies, and reduce timeline risk. Key insights shared ; ✅ The impact of China and Japan on enrolment timelines ✅ Why APAC should be considered at protocol design, not as a rescue strategy ✅ Regulatory developments enabling more seamless global studies ✅ The role of Japan and China in accelerated Oncology development pathways Read the article and discover how a dual-engine APAC strategy could help de-risk and accelerate your next Oncology program. https://lnkd.in/euiUhqsT #OncologyTrials #ClinicalResearch #OncologyDrugDevelopment #GlobalTrials #APAC #ChinaClinicalTrials #JapanClinicalTrials #ClinicalDevelopment #CRO #EmeraldClinical

Meet us at ESMO Madrid booth #1076A Many sponsors still treat APAC as an afterthought in oncology development. The data suggests a different approach. We explore how integrating China and Japan early into global oncology programs can deliver meaningful enrolment acceleration, improve regulatory flexibility, and support faster proof-of-concept decisions In our latest article by Luke S. Gill, Head of Oncology, Will Chen, Global Head of Regulatory Affairs and Rokuya Nochi, Ph.D, MBA of EPS , learn how sponsors can unlock the full potential of APAC in oncology development. https://lnkd.in/etdah_GD #Oncology #ClinicalTrials #DrugDevelopment #China #Japan #APAC #Biotech #EmeraldClinicalESMOESMO - European Society for Medical Oncology

Emerald Clinical runs parallel oncology development across key regions. We combine regulatory strategy, biomarker-driven design and rapid execution. Our China and global approach takes you from first patient to early proof of concept faster. Partner with us to accelerate your oncology program.

Oncology development is complex, slow, and high-risk. Traditional models delay critical go/no-go decisions, costing time, capital and opportunity. Emerald Clinical’s globally integrated early phase model helps you get to proof of concept faster.

Upcoming webinar: "APAC Oncology Trials: Accelerate Global Development Timelines" – taking place on Tuesday, September 22, 2026, in partnership with EPS . Register now and join our leaders Luke S. GillRokuya Nochi, Ph.D, MBA WillChen https://lnkd.in/gyXR6JW3 Explore the strategic role of Asia-Pacific in global oncology development. This webinar will highlight how sponsors can leverage APAC's patient access, regulatory efficiencies, and operational strengths to shorten development timelines, optimize costs, and enhance regulatory outcomes. Key takeaways 🔹 Regulatory pathways and local requirements in China and Japan, including PMDA considerations, CTA processes, ethnic sensitivity, bridging data and GCP requirements 🔹 Common protocol, site selection, enrollment and submission planning mistakes that can create downstream risk and delay program timelines 🔹 How to evaluate when APAC integration makes strategic sense, including realistic expectations for timeline compression and executive-level decision-making #OncologyResearch #ClinicalTrials #BiotechInnovation #RegulatoryAffairs #PatientAccess

We're proud to share that our latest article has been published in the newest edition of International Clinical Trials magazine. Authored by Luke S. Gill, Vice President, Global Head of Oncology, and Dr. Yong Wang, VP, Head of Biostatistics & Clinical Statistical Programming and Data Management, the article explores key considerations shaping clinical development today and highlights the scientific expertise, operational excellence, and collaborative approach that help sponsors navigate increasingly complex development pathways. At Emerald Clinical, we're committed to delivering better evidence, with greater confidence, through deep therapeutic expertise, data-driven decision-making, and global execution excellence. Read the full article here - https://bit.ly/4zuCW1e #ClinicalTrials #ClinicalResearch #DrugDevelopment #ThoughtLeadership #EmeraldClinicalTrials #InternationalClinicalTrials